Increasing numbers of women in the US are getting too little sleep. Inadequate sleep has been associated with impaired metabolic function and endocrine disruption. Sister Study cohort participants (n 5 50,884), completed baseline and follow-up questionnaires on sleep patterns. Incident breast cancers estrogen receptor (ER) status of the tumor were ascertained from questionnaires and medical records. Cox regression was used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs). Analyses of sleep characteristics reported at the first follow-up interview included only participants who were breast cancer-free at time of follow-up interview. Over~7 years of follow-up, 2,736 breast cancer cases (invasive and ductal carcinoma in situ) were diagnosed. There was little evidence that usual sleep duration or other sleep characteristics were associated with breast cancer. However, relative to those with no difficulty sleeping, women who reported having difficulty sleeping 4 nights a week were at an increased risk of overall (HR 5 1.32, 95% CI: 1.09-1.61) and postmenopausal breast cancer (HR 5 1.51, 95% CI 1.24-1.85). Risk of ER1 invasive cancer was elevated for women who reported having a light or television on in the room while sleeping (HR 5 1.20, 95% CI: 0.97-1.47) or who typically got less sleep than they needed to feel their best (HR 5 1.21, 95% CI: 0.98-1.50). In our study, most sleep characteristics, including sleep duration, were not associated with an increased risk although higher risk was observed for some markers of inadequate or poor quality sleep.
Increasing numbers of women in the US are getting too little sleep. Inadequate sleep has been associated with impaired metabolic function and endocrine disruption. Sister Study cohort participants (n 5 50,884), completed baseline and follow-up questionnaires on sleep patterns. Incident breast cancers estrogen receptor (ER) status of the tumor were ascertained from questionnaires and medical records. Cox regression was used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (95% CIs). Analyses of sleep characteristics reported at the first follow-up interview included only participants who were breast cancer-free at time of follow-up interview. Over~7 years of follow-up, 2,736 breast cancer cases (invasive and ductal carcinoma in situ) were diagnosed. There was little evidence that usual sleep duration or other sleep characteristics were associated with breast cancer. However, relative to those with no difficulty sleeping, women who reported having difficulty sleeping 4 nights a week were at an increased risk of overall (HR 5 1.32, 95% CI: 1.09-1.61) and postmenopausal breast cancer (HR 5 1.51, 95% CI 1.24-1.85). Risk of ER1 invasive cancer was elevated for women who reported having a light or television on in the room while sleeping (HR 5 1.20, 95% CI: 0.97-1.47) or who typically got less sleep than they needed to feel their best (HR 5 1.21, 95% CI: 0.98-1.50). In our study, most sleep characteristics, including sleep duration, were not associated with an increased risk although higher risk was observed for some markers of inadequate or poor quality sleep.
Sleep quality is important for an individual's physical and mental health and poor sleep has been associated with numerous chronic diseases. 1 The impact of sleep disruption and short sleep is particularly relevant as the modern work force is trending toward more variable work schedules 2 as well as increasing exposure to electronic screen light in the evenings and to artificial light at night which may be impacting sleep patterns and reducing sleep quality. Inadequate or interrupted sleep and the resulting disruptions in circadian rhythm have been associated with numerous health outcomes, including obesity and metabolic disorders, 3 as well as cancer. 4 In rats, constant light exposure increases susceptibility to the development of mammary tumors. 5 The mechanisms underlying this effect are unknown. Exposure to artificial light at night may suppress melatonin, leading to increases in circulating estrogen levels and modulation of estrogen signaling pathways. 6, 7 Melatonin may also act as a tumor suppressor, therefore lower melatonin levels have the potential to increase risk. 7, 8 Shortened sleep duration, which may be considered a proxy for darkness, is also associated with decreased immune 9 and metabolic function 10, 11 in addition to endocrine disruption. 12 Prior research on self-reported usual sleep duration and breast cancer risk has been meta-analyzed leading to the conclusion that there is little to no association. 8, 13 However, most of the prior studies have been limited to just a single self-reported measure of sleep duration and with only a few studies considering additional relevant factors such as questions regarding sleep quality and/or disruptions, [14] [15] [16] [17] use of medications as sleep aids 14, 17 or timing of sleep (night vs.
day). Additionally, few studies have considered tumor hormone receptor subtype, which is important as risk factors may vary by hormone receptor subtype status. 18 In this prospective study, we evaluated the association between sleep characteristics and exposure to artificial nocturnal light and breast cancer risk with a focus on potential etiologic heterogeneity by estrogen-receptor (ER) status of the tumor.
Material and Methods

Study population
The Sister Study is a prospective cohort study (n 5 50,884) designed to evaluate environmental and genetic risk factors for breast cancer development. Women without a personal history of breast cancer were recruited between 2003 and 2009 using a multimedia campaign and a network of breast cancer advocates and professionals. Eligibility criteria included being between the ages 35 and 74, living in the United States or Puerto Rico, and having a sister who had been diagnosed with breast cancer. The Sister Study was approved by the Institutional Review Board of the National Institute of Environmental Health Sciences. All study participants provided written informed consent. In this analysis, we used data from the Sister Study Data Release 5.01, which included cases diagnosed up to August 31st, 2015.
At study baseline, participants completed an extensive computer-assisted telephone interview, in which they reported information on their demographics, medical and family history and lifestyle factors including sleep patterns and characteristics (Fig. 1) . During the study follow-up period, participants completed detailed questionnaires (every 2-3 years) and annual health updates on current risk factor information and to notify the study of changes in health. In 2012-2014, the detailed follow-up questionnaire included additional information on sleep patterns. The participation rate for the sleep follow-up questionnaire was 84%. Study participants who completed the follow-up questionnaire were slightly more likely to be non-Hispanic white, but other demographic and lifestyle factors were similar to those of the baseline study population.
Outcome assessment
Incident breast cancer cases, including both ductal carcinoma in situ (DCIS) and invasive disease, were ascertained via annual health updates and detailed follow-up questionnaires. Women reporting breast cancer were asked for consent to obtain their medical records to confirm the diagnosis and obtain additional information on tumor characteristics including extent of disease (invasive or in situ), stage and estrogen receptor (ER1 vs. ER-) status. For this data release, 81.1% of medical records had been successfully obtained.
When medical record information was not available, selfreported information was used based on very high agreement (https://sisterstudy.niehs.nih.gov/English/brca-validation.htm).
Exposure and covariate assessment
As part of the baseline questionnaire, women were asked detailed questions about their sleep patterns, including whether they sleep during the daytime or nighttime, their usual sleep duration, the length of time it takes to go to sleep, any types of light present while sleeping, frequency of waking up at night, frequency of naps and sleep medication use. During follow-up, more questions on sleep were asked, including how much sleep the individual needs to feel their best and their usual sleep duration in the year prior to follow-up. From these questions, we classified the participants as getting as much or more sleep than they felt they needed or less sleep than they felt that they needed. Participants also reported if they had difficulty sleeping, felt excessively sleepy during the day, or acted out their dreams (physical enactment of dreams while sleeping). Study questionnaires are available on the Sister Study Website (www.sisterstudy.niehs. nih.gov).
From the baseline study interview, information on demographics (race/ethnicity, education, income and marital status), reproductive history, lifestyle factors such as smoking and alcohol consumption and use of exogenous hormones was obtained. Menopausal status (premenopausal vs. postmenopausal) was determined from questionnaire data and updated throughout follow-up. Height and weight at baseline were measured in a home visit by a trained examiner and used to calculate body mass index (BMI, kg/m 2 ).
Statistical analysis
We excluded the small proportion of women in the cohort who were diagnosed with invasive or DCIS breast cancer prior to completion of the baseline interview (n 5 76), were currently shift workers (n 5 269) or who were blind (n 5 6). We excluded current shift workers as they would likely have disrupted sleep patterns because of their shift work but the sample size was too small to stratify on shift working status. The final analytic sample size was n 5 50,533 (99%).
Descriptive statistics were compared for study participants stratified by usual sleep duration as assessed at baseline. To evaluate the association between baseline sleep characteristics and breast cancer risk, adjusted Cox proportional hazards
What's new?
This new study has uncovered a link between poor sleep and breast cancer risk. We already know that good quality sleep benefits health in many ways. The authors evaluated sleep habits and the association with breast cancer using detailed questionnaire data women provided when they enrolled in a cohort study. They determined that most sleep characteristics-including hours of sleep per night-did not correlate with cancer risk. However, women who reported difficulty falling asleep most nights, those with lights or TVs on in the room and those who felt they did not get enough sleep, showed a significant boost to their risk of breast cancer. models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI). The time scale for the Cox model was age with person-time accruing from age at study enrollment to age at breast cancer diagnosis or age of last follow-up.
The analyses of sleep characteristics assessed at the followup interview were limited to women who were breast cancerfree when they completed the follow-up interview (n 5 41,474). For these variables, the time scale of the Cox model was leftcensored at age of follow-up interview, meaning that study participants entered the Cox model at age of follow-up interview and remained in the model until their age of breast cancer diagnosis, censoring event, or end of follow-up, whichever occurred first.
We also evaluated the association between sleep characteristics and breast tumor estrogen receptor status (ER1, ER-), extent (invasive, DCIS) and menopausal status at diagnosis (premenopausal, postmenopausal). For ER-specific analyses, cases without the outcome of interest were censored at the time of diagnosis. The analyses of ER subtype were limited to invasive tumors only, as ER status information is less complete for in situ cases. For the sleep characteristics assessed at the time of follow-up interview, we were unable to consider associations with ER-tumors as there were few subsequent ER-cases. To evaluate differences by ER status, we conducted a case-case analysis comparing ER1 to ER-breast cancer. When considering premenopausal breast cancer as an outcome, women who became postmenopausal during the follow-up period were censored at age of menopause. The women who reached menopause without developing breast cancer then contributed person-time to the postmenopausalspecific analyses.
The proportional hazards assumption was assessed using an interaction term with survival time in the regression model and with log-log survival plots. We found no evidence of time-variation in the HR associations.
Sleep medication use in the prior six weeks (yes, no) and BMI at baseline were assessed as potential effect measure modifiers for the relationship between the different sleep characteristics and breast cancer. We also considered whether the associations between measures of sleep quality and breast cancer risk were modified by sleep duration. A cross-product term and likelihood ratio test was used to evaluate interactions on the multiplicative scale.
We also considered whether changes in sleep duration over time were associated with breast cancer risk by evaluating whether sleep duration stayed the same, increased or decreased from baseline to follow-up. We used categorical variables (6, 7-8 and 9 hrs), so an individual was characterized as having increased or decreased sleep if their reported sleep duration at the follow-up interview fell into a different category.
Confounders were identified using the prior literature and a directed acyclic graph. 19 Multivariable-adjusted models included covariates assessed at baseline, including race (nonHispanic white, other), education (high school or equivalent, some college, 4-year degree or higher), household income (<49,999, 50,000-99,999 and 100,0001), marital status (never married, legally married or living as married, separated or divorced or widowed), hormone replacement therapy use (none, estrogen only, progesterone only or combination therapy), use of oral contraceptives (ever, never), alcohol consumption (never, former, current drinker 1 
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drink/day, current drinker >1 drink/day), age at menarche (continuous), parity (nulliparous or 1, 2-3 and 4), age at first birth (<21 years, 21-24, 25-28, 29-31 and 32), age at menopause (premenopausal, <40, 40-50, 51-55 and >55 years based on enrollment information), pack-years of smoking (never smoker, smoker <20 pack-years, smoker 20 pack-years) and metabolic equivalent hours of physical activity per week (<27.0, 27.0-44.3, 44.4-67.1 and >67.2). Missing data on adjustment covariates was minimal (<3% total) and thus, we did a complete case analysis. We also conducted a sensitivity analysis in which BMI was included as a confounder in the adjustment set.
To address the possibility of reverse causality, we conducted sensitivity analyses limiting to cases diagnosed after the first two years of study follow-up after baseline. For the analyses investigating the association between sleep characteristics at follow-up and breast cancer, we excluded all cases diagnosed prior to the follow-up interview. Additionally, we conducted an analysis evaluating the time to diagnosis by sleep characteristics ascertained at the follow-up survey.
To assess the validity of self-reported sleep characteristics over time, we conducted some additional analyses to evaluate the similarity of sleep characteristics reported at baseline and at follow-up in women who were not diagnosed with breast cancer. First, we determined the correlation between continuous measures and calculated a weighted kappa (6, 7-8 and 9 hr) for sleep duration at baseline and follow-up. Second, we evaluated the average sleep duration at baseline by whether the participant reported getting enough sleep at follow-up. We also evaluated whether those who reported sleep disruption at baseline (frequency of night waking per month and times waking up per night) were more likely to report difficulty sleeping at follow-up. Two-sided tests were used with a p values of 0.05 to evaluate statistical significance. All analyses were performed using SAS version 9.3 software (SAS Institute, Cary, NC).
Results
From baseline to the end of follow-up, 2,736 breast cancers were diagnosed during 375,925 person-years of follow-up [mean 5 7.4, standard deviation (SD) 5 2.0]. On average, women reported getting about 7 hr of sleep per night at baseline (mean 5 7.1, SD 5 1.1). Almost a quarter of the study population reported getting insufficient sleep (6 hr) on average, whereas only 7% got 9 or more hours of sleep (Table  1) . Women who reported 6 hr sleep at baseline were more likely to be non-white and to be of a lower socioeconomic status, with both lower educational attainment and lower annual household income. They were also less likely to be married or living as married. Long sleepers (9 hr) were slightly older, were more likely to consume more than one alcoholic drink per day and more likely to use postmenopausal hormones.
Sleep characteristics assessed at baseline, including usual sleep duration, time it takes to fall asleep and waking at night, were not consistently associated with an increased risk of overall breast cancer (Table 2 ). There was some evidence that sleeping 6 hrs was associated with ER-breast cancer (HR 5 1.26, 95% CI: 0.92-1.73) but not ER1 (HR 5 0.87, 95% CI: 0.76-1.00) relative to sleeping 7 hr a night. CI for these associations were wide and a case-case comparison of the association between getting 6 or fewer hours and ER1 versus ER-breast cancer was not statistically significant (p 5 0.2). There were no associations observed with other baseline sleep characteristics including time to sleep, waking at night or sleep medication use. Additionally, no associations were observed with increasing frequency of sleep medication use and frequency of napping (data not shown).
Among women completing the first follow-up questionnaire, usual sleep duration in the year prior to follow-up was similarly not associated with breast cancer (Table 3) . However, reporting having difficulty sleeping 4 nights per week was associated with an increased risk of overall breast cancer (HR 5 1.32, 95% CI: 1.09-1.61) compared with having no difficulty sleeping. Elevated HRs for ER1 breast cancer were observed for women who reported needing 9 hr of sleep to feel their best relative to needing 7-8 hr (HR 5 1.29, 95% CI: 0.98-1.70) and for women who were getting less sleep than they felt they needed (HR 5 1.21, 95% CI: 0.98-1.50). Feeling excessively sleepy during the daytime was not associated with a higher risk of breast cancer. No association was observed with changes in sleep duration over time (data not shown). Elevated HRs for measures of difficulty sleeping were also evident in analyses restricted to postmenopausal (but not premenopausal) breast cancer (Table 4) . For example, difficulty sleeping on a regular basis was associated with a higher risk of postmenopausal breast cancer (HR 5 1.21, 95% CI:1.03-1.43); especially for difficulty sleeping on >4 days a week (HR 5 1.51, 95% CI 1.24-1.85).
Variables related to exposure to nighttime light are shown in Table 5 . Compared with women who had no light on while sleeping or who slept with a mask on, sleeping with artificial light on in the room (defined as a light or television) was associated with an elevated HR of ER1 tumors (HR 5 1.20, 95% CI 0.97, 1.47), but not ER-tumors (HR 5 0.97, 95% CI: 0.61-1.55; Table 5 ). Similarly, slightly elevated HRs for ER1 tumors were observed for sleeping with artificial light coming from outside the room (HR 5 1.11, 95% CI 0.96-1.30), although results were not statistically significant.
Including BMI in the models did not notably change the estimates of association (data not shown) nor did it act as an effect measure modifier of associations. Results were similar by breast tumor stage and for invasive disease versus DCIS (data not shown). Self-reported use of any sleep medication and sleep duration did not modify the associations between other sleep characteristics and breast cancer risk (data not shown).
Excluding cases diagnosed in the first two years of study follow-up did not alter results or study conclusions (data not shown). Similarly, time from follow-up survey to diagnosis did not notably vary by follow-up sleep characteristics. For example, time to diagnosis was similar when comparing those who reported no difficulty sleeping on a regular basis (mean-5 2.2 years, range 0.1-3.5 years) and those who did (mean-5 2.2 years, range 0.1-3.5 years). This finding was consistent across other follow-up sleep characteristics.
There was moderate correlation between usual sleep duration at baseline and at follow-up (continuous correlation, r 5 0.52; categorical weighted kappa, k 5 0.38). Study participants who got enough sleep to feel their best at follow-up reported a median baseline usual sleep duration of 8 hr, whereas women who were not getting enough sleep reported a median of 7 hr of sleep per night. There was also evidence to support that women who indicated they had more disrupted sleep at baseline (determined as increasing frequency of night waking per month and times waking up per night) Adjusted for race, education, income, marital status, postmenopausal hormone use, use or oral contraceptives, alcohol consumption, age at menarche, parity, age at first birth, age at menopause, pack years of smoking and physical activity.
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were also more likely to say they had difficulty sleeping at the follow-up visit. For example, compared to those who reported never waking up at night, those who reported waking up 31 times per night at baseline were more likely to report having difficulty sleeping at the follow-up survey (67 vs. 23%).
Discussion
In this large prospective study of women at risk for breast cancer, most sleep characteristics, including usual sleep duration, were not associated with an increased risk of breast cancer. However, we did observe that frequently having difficulty of sleeping or sleeping with a television or light on in the room were associated with an increased risk of breast cancer. Not getting enough sleep to feel one's best was also associated with breast cancer risk. These sleep characteristics may be indicators of diminished sleep quality. The findings from this study suggest that although most sleep characteristics were not strongly related to breast cancer risk, improved measures of sleep quality may be needed to better understand the role, if any, sleep disturbance has in the etiology of breast cancer. Few studies have considered markers of sleep quality and other sleep characteristics in association with breast cancer. Two prior studies did not observe an association using selfreported sleep quality on a 4-point scale (poor, fairly poor, fairly good and good). 15, 16 In the Women's Health Initiative, no association was observed for having insomnia, reporting restless sleep or for a composite score of sleep disturbances. 17 Sleep disturbance metrics were not related to breast cancer risk in a case-control study in Australia.
14 Our finding, of elevated risk associated with difficulty sleeping, particularly in postmenopausal women, contrasts with these prior studies.
We also noted an elevated risk for ER1 breast cancer associated with a personalized determination of getting less sleep than participants needed. The association in our study that was most pronounced was in women who had difficulty sleeping most days of the week and may reflect more chronic sleep disruption. We also observed elevated HRs with exposure to artificial light at night, especially for ER1 breast tumors. Although not statistically significant, the point estimates are consistent with other studies that have largely shown positive associations between artificial light at night exposure and breast cancer risk [20] [21] [22] [23] [24] and are in line with a meta-analysis reporting a 17% increase in overall breast cancer risk for artificial light exposure. 8 We were limited by not having additional information about artificial light in the evenings prior to bedtime or on duration of light exposure during sleep.
One candidate mechanism underlying the association between circadian disruption and breast cancer involves altered estrogen signaling from reduced melatonin production. 12 In a meta-analysis, reduced levels of melatonin was found to be associated with an increased risk of breast cancer. 8 Circadian disruption may also impact processes important for normal cellular function such as cell-cycle regulation, DNA repair and apoptosis by alterations in the expression of the CLOCK gene. 12, 25 Another possible mechanism is through altered immune function and metabolism. 25 Inadequate or interrupted sleep has been associated with diabetes and obesity, 26 chronic inflammation 12 and cardiovascular disease. 27 Decreased sleep may impact obesity via influencing hormone levels such as leptin and ghrelin, which are important in controlling appetite and energy expenditure 11 . In this cohort, we have also previously reported sleep duration to be associated with patterns of less favorable eating behaviors such as snacking, 28 suggesting that inadequate sleep may also be a marker of poor health behaviors.
We found that the associations with exposure to artificial light at night were more evident for ER-positive breast cancer. Circadian disruption reduces melatonin production, which in turn increases circulating estrogen levels, and would be hypothesized to increase the risk of ER-positive disease. 12 Thus, these findings are consistent with the idea that the biologic mechanism of these associations may be related to estrogen signaling pathways.
Previous studies have reported a mix of positive, negative and null results for the association between sleep duration and breast cancer risk, but meta-analyses have found little evidence of heterogeneity, 8, 13, [15] [16] [17] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] and have largely concluded null associations. 8, 13, 39 Some studies have shown variability in sleep duration with ER status with a decreased risk for ER1 breast cancer with short sleep and an increased risk for ER-breast cancer with short sleep. 17, 34, 37 Although we saw suggestive differences in risk estimates for ER1 and ERbreast cancer, these estimates were not appreciably different. These studies and ours have relied on self-reported usual sleep duration, which is subject to misclassification, 40 which may account for differences across studies.
Addressing the role of BMI in the sleep and breast cancer relationship is challenging. Obesity is a risk factor for postmenopausal breast cancer 41 and is associated with sleep quality 42 and duration. 43 Given that BMI and baseline sleep characteristics were measured at the same time, we cannot determine the temporal order. Therefore, it is possible that BMI could be on the casual pathway between sleep duration and breast cancer or vice versa. Therefore, we chose to not adjust for BMI in our main analysis as adjusting for a mediator may induce bias. 44 However, to address the possibility that BMI is influencing sleep patterns, we considered a sensitivity analysis where BMI was included as a covariate in the model and our results were largely unchanged. Stratifying on BMI did also not show evidence that BMI was an important effect measure modifier of this relationship.
Our study included an extensive questionnaire on sleep characteristics and patterns, including on sleep duration and quality as well as exposure to artificial light at night, with data collected at two separate time points prior to breast cancer diagnosis. This allowed us to consider a wide array of possible sleep-related factors that could be relevant for breast cancer and to evaluate sleep medication use. The Sister Study had a small number of current shift workers, which may reflect the study population's demographic composition. As such, we excluded current shift workers from our study population as shift work both alters sleep schedules and may independently influence breast cancer risk, 45 although the latter has recently been called into question. 46 We attempted to address the possibility of reverse causation by excluding cases that occurred during the first two years of follow-up and the associations with the baseline sleep characteristics remained the same. This approach was not possible for the characteristics only assessed at follow-up interview due to the smaller number of cases diagnosed after the second interview. Therefore, we evaluated whether time to diagnosis varied by follow-up sleep characteristics and found no evidence to support that reverse causation was impacting our results. However, we cannot rule out the possibility that an undiagnosed breast tumor or other unknown factors (such as underlying comorbidities) may be disrupting sleep and thus impacting breast cancer risk.
Some limitations should be considered in the interpretation of our results. Prior studies have shown misclassification for self-reported sleep duration, 40 which may extend to other sleep characteristics.
However, comparison of responses across our baseline and follow-up survey, showed reasonable consistency in reporting sleep duration and disrupted sleep, supporting the use of self-reported data. It is also possible that difficulty sleeping at night and artificial light at night exposure may be more memorable and easily reported than determining the usual hours of sleep. Unfortunately, most sleep tracking devices are not very reliable at measuring sleep disruption, 47 and thus future technological advances may be necessary to ensure that sleep tracking devices or smartphones can be used to adequately measure sleep disruptions. Although we saw no increase in risk for any sleep medication use or increasing frequency of sleep medication use in the last six weeks, we did not consider more detailed information on specific types of medications or historic medication use; frequent use of hypnotics has been previously found to be modestly related to breast cancer risk.
